About Invo Bioscience (OTCMKTS:IVOB)
INVO Bioscience, Inc. is a medical device company. The Company is focused on creating various treatments for patients diagnosed with infertility. The Company's product, the INVOcell, is a medical device used in infertility treatment and is considered as an assisted reproductive technology (ART). INVOcell is an intravaginal culture (IVC) system used for preparing, holding and transferring human gametes or embryos during vaginal in vitro fertilization or intravaginal culture procedures (IVF/IVC). The INVOcell system consists of various components: INVOcell Culture Device, INVOcell Retention Device and INVOcell Holding Block. The INVO Procedure is a fertility treatment option allowing fertilization and early embryo development to take place inside the woman's body. The INVO Procedure is an IVC or in vivo incubation assisted reproduction technique available.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / Sales1,161.78
Price / CashN/A
Book Value($0.03) per share
Price / Book-13.67
Return on EquityN/A
Return on Assets-367.53%
Invo Bioscience (OTCMKTS:IVOB) Frequently Asked Questions
What is Invo Bioscience's stock symbol?
Invo Bioscience trades on the OTCMKTS under the ticker symbol "IVOB."
How were Invo Bioscience's earnings last quarter?
Invo Bioscience Inc (OTCMKTS:IVOB) released its earnings results on Monday, May, 15th. The company reported $0.00 earnings per share for the quarter. The business had revenue of $0.05 million for the quarter. View Invo Bioscience's Earnings History.
When will Invo Bioscience make its next earnings announcement?
Who are some of Invo Bioscience's key competitors?
Some companies that are related to Invo Bioscience include Sunesis Pharmaceuticals (SNSS), BioDelivery Sciences International (BDSI), Oncomed Pharmaceuticals (OMED), Bellerophon Therapeutics (BLPH), Mediwound (MDWD), Ophthotech (OPHT), Kalvista Pharmaceuticals (KALV), Aptose Biosciences (APTO), Advaxis (ADXS), AcelRx Pharmaceuticals (ACRX), Trillium Therapeutics (TRIL), Agile Therapeutics (AGRX), Cumberland Pharmaceuticals (CPIX), Leap Therapeutics (LPTX), Bioline RX (BLRX), ProQR Therapeutics (PRQR), Gemphire Therapeutics (GEMP) and KemPharm (KMPH).
Who are Invo Bioscience's key executives?
Invo Bioscience's management team includes the folowing people:
- Kathleen T. Karloff, Chairman of the Board, President, Chief Executive Officer
- Robert J. Bowdring, Chief Financial Officer, Treasurer, Secretary, Director
- Kevin Doody, Director
- Michael J. Campbell, Independent Director
- Stephen M. Shum, Independent Director
Has Invo Bioscience been receiving favorable news coverage?
News articles about IVOB stock have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Invo Bioscience earned a media sentiment score of 0.19 on Accern's scale. They also assigned media stories about the company an impact score of 45.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Invo Bioscience?
Shares of IVOB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invo Bioscience's stock price today?
One share of IVOB stock can currently be purchased for approximately $0.41.
How big of a company is Invo Bioscience?
Invo Bioscience has a market capitalization of $58.09 million and generates $50,000.00 in revenue each year. Invo Bioscience employs 3 workers across the globe.
How can I contact Invo Bioscience?
Invo Bioscience's mailing address is 407R MYSTIC AVENUE SUITE 34C, MEDFORD MA, 02155. The company can be reached via phone at 978-878-9505 or via email at info[email protected]
MarketBeat Community Rating for Invo Bioscience (IVOB)MarketBeat's community ratings are surveys of what our community members think about Invo Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Invo Bioscience (OTCMKTS:IVOB) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Invo Bioscience (OTCMKTS:IVOB) Earnings History and Estimates Chart
Invo Bioscience (OTCMKTS IVOB) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/19/2018|| || || || || || || || |
|5/15/2017||Q1 2017||$0.00||$0.05 million||View||N/A|
Invo Bioscience (OTCMKTS:IVOB) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Invo Bioscience (OTCMKTS:IVOB)
No dividend announcements for this company have been tracked by MarketBeat.com
Invo Bioscience (OTCMKTS IVOB) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 0.04%
Invo Bioscience (OTCMKTS IVOB) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/5/2018||Claude Ranoux||Major Shareholder||Sell||13,642||$0.18||$2,455.56|| |
|2/23/2018||Claude Ranoux||Major Shareholder||Sell||100||$0.18||$18.00|| |
|2/21/2018||Claude Ranoux||Major Shareholder||Sell||122,322||$0.11||$13,455.42|| |
|2/16/2018||Claude Ranoux||Major Shareholder||Sell||13,890||$0.11||$1,527.90|| |
|2/13/2018||Claude Ranoux||Major Shareholder||Sell||12,808||$0.11||$1,408.88|| |
|2/7/2018||Claude Ranoux||Major Shareholder||Sell||16,115||$0.11||$1,772.65|| |
|2/2/2018||Claude Ranoux||Major Shareholder||Sell||18,700||$0.12||$2,244.00|| |
|1/29/2018||Claude Ranoux||Major Shareholder||Sell||31,319||$0.12||$3,758.28|| |
|1/25/2018||Claude Ranoux||Major Shareholder||Sell||2,100||$0.12||$252.00|| |
|1/22/2018||Claude Ranoux||Major Shareholder||Sell||46,500||$0.12||$5,580.00|| |
|1/16/2018||Claude Ranoux||Major Shareholder||Sell||600||$0.15||$90.00|| |
|1/12/2018||Claude Ranoux||Major Shareholder||Sell||12,545||$0.15||$1,881.75|| |
|1/8/2018||Claude Ranoux||Major Shareholder||Sell||100,000||$0.13||$13,000.00|| |
|1/4/2018||Claude Ranoux||Major Shareholder||Sell||2,834||$0.15||$425.10|| |
|12/29/2017||Claude Ranoux||Major Shareholder||Sell||4,525||$0.16||$724.00|| |
|12/27/2017||Claude Ranoux||Major Shareholder||Sell||10,000||$0.17||$1,700.00|| |
|12/20/2017||Claude Ranoux||Major Shareholder||Sell||10,000||$0.17||$1,700.00|| |
|12/18/2017||Claude Ranoux||Major Shareholder||Sell||30,000||$0.17||$5,100.00|| |
|12/11/2017||Claude Ranoux||Major Shareholder||Sell||50,000||$0.18||$9,000.00|| |
Invo Bioscience (OTCMKTS IVOB) News Headlines
|INVO Bioscience Expands its Training Capacity|
finance.yahoo.com - March 13 at 10:14 AM
|INVOcell Fertility Treatment Now Offered at Family Beginnings in Indianapolis|
finance.yahoo.com - March 6 at 9:40 AM
|INVO Bioscience Progresses in Developing Market for INVOcell in Hong Kong and Macao|
finance.yahoo.com - February 28 at 9:41 AM
|Claude Ranoux Sells 122,322 Shares of Invo Bioscience Inc (IVOB) Stock|
www.americanbankingnews.com - February 22 at 7:26 PM
|Alabama Fertility Breaking New Ground to be the First to Offer INVOcell in Alabama|
finance.yahoo.com - February 20 at 9:19 AM
|Carolina Conceptions Expands its Menu of Reproductive Services with INVOcell|
finance.yahoo.com - February 8 at 9:07 AM
|Invo Bioscience Inc (IVOB) Major Shareholder Claude Ranoux Sells 100,000 Shares|
www.americanbankingnews.com - January 9 at 7:56 PM
|INVO Bioscience Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 15 at 3:24 AM
|INVO Bioscience Appoints Michael J. Campbell and Steven Shum to Its Board of Directors|
finance.yahoo.com - October 11 at 4:48 PM
|First INVO Babies Born in California|
finance.yahoo.com - September 25 at 9:23 AM
|Dr. Francisco Arredondo Opens First U.S. INVOcell Center in McAllen, Texas|
finance.yahoo.com - September 6 at 7:59 PM
|INVO Bioscience Reports Record Second Quarter 2017 Financial Results|
finance.yahoo.com - August 11 at 4:37 AM
|INVOcell Fertility Treatment Now Offered at the Center for Reproductive Health at Tri-Star Centennial Medical Center in Nashville|
finance.yahoo.com - August 3 at 8:14 PM
|Piedmont Reproductive Endocrinology Group in South Carolina Successfully Launches INVOcell|
finance.yahoo.com - August 2 at 1:34 AM
|Houston Fertility Center to Begin Offering INVOcell Procedure to Patients in Southeast Texas|
finance.yahoo.com - July 19 at 10:40 PM
|The Atlantic Magazine Publishes Article on Breakthrough IVF Treatment by INVO Bioscience|
finance.yahoo.com - July 14 at 4:44 AM
|INVO BIOSCIENCE, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 17 at 6:14 PM
|INVO BIOSCIENCE, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Amendments to Articles of In|
biz.yahoo.com - January 6 at 6:39 PM
|INVO BIOSCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - September 26 at 5:47 PM
|INVO BIOSCIENCE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - November 3 at 11:59 AM
Invo Bioscience (OTCMKTS:IVOB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Invo Bioscience (OTCMKTS IVOB) Stock Chart for Monday, March, 19, 2018